Farzam, K., & Patel, P. (2024, February 20). Tirzepatide . StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK585056/#:~:text=Tirzepatide%20is%20a%20dual%20agonist,1%20medications%20such%20as%20semaglutide Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2020). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in Type 2 diabetes. the Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism , 106 (2), 388–396. https://doi.org/10.1210/clinem/dgaa863 Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020). The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism , 22 (12), 2451–2459. https://doi.org/10.1111/dom.14174

Information for Tirzepatide

Tirzepatide (LY3298176) is a 39-amino acid synthetic peptide designed as a dual agonist of GIP and GLP-1 receptors, exhibiting a prolonged half-life due to a C20 fatty diacid side chain that promotes albumin binding (Chavda et al. 2022). Experimental models show its dual receptor activation enhances metabolic regulation and induces dose-dependent reductions in fat mass with a preference for adiposity over lean mass (Min & Bain 2020; Karagiannis et al. 2022; Sokary & Bawadi 2025).

References

Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022). Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315

Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia, 65, 1251–1261.
https://doi.org/10.1007/s00125-022-05715-4

Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy, 11(9), 1941–1957. https://doi.org/10.1007/s13300-020-00981-0

Sokary, S., & Bawadi, H. (2025). The promise of tirzepatide: A narrative review of metabolic benefits. Primary Care Diabetes, 19(3), 229–237. https://doi.org/10.1016/j.pcd.2025.03.008

Order Tirzepatide 10mg

Order Tirzepatide 15mg

Order Tirzepatide 30mg

Order Tirzepatide 60mg

Order GMP Tirzepatide 15mg

Order GMP Tirzepatide 30mg

GMP Certificates of Analysis

Tirzepatide<br>9.79mg<br>Laboratory ID V250930-12 007<br>10/15/2025

Tirzepatide
9.79mg
Laboratory ID V250930-12 007
10/15/2025

Tirzepatide<br>15.26mg<br>Laboratory ID V250930-12 008<br>10/15/2025

Tirzepatide
15.26mg
Laboratory ID V250930-12 008
10/15/2025

Tirzepatide<br>30mg<br>Laboratory ID V250826-9 004<br>09/12/2025

Tirzepatide
30mg
Laboratory ID V250826-9 004
09/12/2025

Tirzepatide<br>27.05mg<br>Laboratory ID V250606-26 007<br>06/20/2025

Tirzepatide
27.05mg
Laboratory ID V250606-26 007
06/20/2025

Tirzepatide<br>15.02mg<br>Laboratory ID V250606-26 006<br>06/20/2025

Tirzepatide
15.02mg
Laboratory ID V250606-26 006
06/20/2025

Older GMP Certificates of Analysis

Tirzepatide 9.54 Laboratory ID V250606-26 005 06/20/2025

Tirzepatide 10 Laboratory ID V250321-20 010 04/02/2025

Tirzepatide 30 Laboratory ID V250321-20 010 04/02/2025

Tirzepatide 10.1 Batch PKTZ1011525 01/15/2025

Tirzepatide 30.05 Batch PKTZ30121024 12/10/2024

Tirzepatide 15.2 Batch PKTZ15924 09/10/2024

Tirzepatide 30.1 Batch PKTZ30924 09/10/2024

Research Certificates of Analysis

Tirzepatide<br>
11.04mg<br>Laboratory ID V250915-17 002<br>10/02/2025

Tirzepatide
11.04mg
Laboratory ID V250915-17 002
10/02/2025

Tirzepatide<br>
33.45mg<br>Laboratory ID V250826-9 003<br>09/12/2025

Tirzepatide
33.45mg
Laboratory ID V250826-9 003
09/12/2025

Tirzepatide<br>
63.29mg<br>Laboratory ID V250606-26<br>06/20/2025

Tirzepatide
63.29mg
Laboratory ID V250606-26
06/20/2025

Tirzepatide<br>
10.15mg<br>Laboratory ID V250131-1<br>02/27/2025

Tirzepatide
10.15mg
Laboratory ID V250131-1
02/27/2025

Tirzepatide<br>
22.06mg<br>Laboratory ID V250131-1<br>02/27/2025

Tirzepatide
22.06mg
Laboratory ID V250131-1
02/27/2025

Older Research Certificates of Analysis

Tirzepatide 33.66 Laboratory ID V250131-1 02/27/2025

Tirzepatide 33.78 Batch #1002 11/11/2024

Tirzepatide 30.02 Batch 09122024 09/12/2024

Tirzepatide 34.15 Batch T30-001 08/02/2024

Tirzepatide 12.06 Batch FTIR-0001 08/01/2024

Tirzepatide 30.25 Batch 04162024 04/23/2024

Tirzepatide 17.74 Batch 04072024 04/12/2024

Tirzepatide Peptide Structure

Source: PubChem

PubChem Identifier: CID 156588324

Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ (C20 fatty acid) AFVQWLIAGGPSSGAPPPS
Note: Aib is a non-coded (non-proteinogenic) amino acid – H2H-C(CH3)2-COOH

Molecular Formula: C225H348N48O68

Molecular Weight: 4813.527 g/mol

CAS Number: 2023788-19-2

Synonyms: P1206, LY3298176

Order Tirzepatide 10mg

Order Tirzepatide 15mg

Order Tirzepatide 30mg

Order Tirzepatide 60mg

Order GMP Tirzepatide 15mg

Order GMP Tirzepatide 30mg

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.

Order Tirzepatide 10mg

Order Tirzepatide 15mg

Order Tirzepatide 30mg

Order Tirzepatide 60mg

Order GMP Tirzepatide 15mg